Les stéatopathies métaboliques : conséquences hépatiques du syndrome métabolique

Ludwig, 1980, Nonalcoholic steatohepatitis. Mayo clinic experiences with a hitherto unnamed disease, Mayo Clin Proc, 55, 434 Brunt, 1999, Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions, Am J Gastroenterol, 94, 2467, 10.1111/j.1572-0241.1999.01377.x Neuschwander-Tetri, 2003, Nonalcoholic steatohepatitis: summary of an AASLD single topic conference, Hepatology, 37, 1202, 10.1053/jhep.2003.50193 Brunt, 2004, Nonalcoholic steatohepatitis, Semin Liver Dis, 24, 3, 10.1055/s-2004-823098 Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 Marchesini, 2003, Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome, Hepatology, 37, 917, 10.1053/jhep.2003.50161 Fan, 2005, Fatty liver and the metabolic syndrome among Shanghai adults, J Gastroenterol Hepatol, 20, 1825, 10.1111/j.1440-1746.2005.04058.x Vague, 1956, The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease, Am J Clin Nutr, 4, 20, 10.1093/ajcn/4.1.20 Reaven, 1993, Role of insulin resistance in human disease (syndrome X): an expanded definition, Annu Rev Med, 44, 121, 10.1146/annurev.me.44.020193.001005 2002, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143 Alberti, 2006, Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation, Diabet Med, 23, 469, 10.1111/j.1464-5491.2006.01858.x Soto Gonzalez, 2007, Predictors of the metabolic syndrome and correlation with computed axial tomography, Nutrition, 23, 36, 10.1016/j.nut.2006.08.019 Lefebvre, 1998, Depot-specific differences in adipose tissue gene expression in lean and obese subjects, Diabetes, 47, 98, 10.2337/diabetes.47.1.98 Tilg, 2006, Adipocytokines: mediators linking adipose tissue, inflammation and immunity, Nat Rev Immunol, 6, 772, 10.1038/nri1937 Rosen, 2006, Adipocytes as regulators of energy balance and glucose homeostasis, Nature, 444, 847, 10.1038/nature05483 Virkamaki, 1999, Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance, J Clin Invest, 103, 931, 10.1172/JCI6609 Donnelly, 2005, Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease, J Clin Invest, 115, 1343, 10.1172/JCI23621 Yki-Jarvinen, 2002, Ectopic fat accumulation: an important cause of insulin resistance in humans, J R Soc Med, 95, 39 Petersen, 2005, Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes, Diabetes, 54, 603, 10.2337/diabetes.54.3.603 Farrell, 2006, Nonalcoholic fatty liver disease: from steatosis to cirrhosis, Hepatology, 43, S99, 10.1002/hep.20973 Badman, 2007, The adipocyte as an active participant in energy balance and metabolism, Gastroenterology, 132, 2103, 10.1053/j.gastro.2007.03.058 Shoelson, 2007, Obesity, inflammation, and insulin resistance, Gastroenterology, 132, 2169, 10.1053/j.gastro.2007.03.059 Tilg, 2006, Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance, Gastroenterology, 131, 934, 10.1053/j.gastro.2006.05.054 Ikejima, 2001, Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals, Hepatology, 34, 288, 10.1053/jhep.2001.26518 Leclercq, 2002, Leptin is essential for the hepatic fibrogenic response to chronic liver injury, J Hepatol, 37, 206, 10.1016/S0168-8278(02)00102-2 Chalasani, 2003, Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis ?, Am J Gastroenterol, 98, 2771, 10.1111/j.1572-0241.2003.08767.x Angulo, 2004, Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease, J Hepatol, 41, 943, 10.1016/j.jhep.2004.08.020 Larter, 2006, Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat?, J Hepatol, 44, 253, 10.1016/j.jhep.2005.11.030 Yamauchi, 2003, Cloning of adiponectin receptors that mediate antidiabetic metabolic effects, Nature, 423, 762, 10.1038/nature01705 Yamauchi, 2007, Targeted disruption of Adipo R1 and Adipo R2 causes abrogation of adiponectin binding and metabolic actions, Nat Med, 13, 332, 10.1038/nm1557 Schaffler, 2005, Mechanisms of disease: adipocytokines and visceral adipose tissue-emerging role in nonalcoholic fatty liver disease, Nat Clin Pract Gastroenterol Hepatol, 2, 273, 10.1038/ncpgasthep0186 Xu, 2003, The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice, J clin Invest, 112, 91, 10.1172/JCI200317797 Whitehead, 2006, Adiponectin-a key adipokine in the metabolic syndrome, Diabetes Obes Metab, 8, 264, 10.1111/j.1463-1326.2005.00510.x Bugianesi, 2005, Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity, J Clin Endocrinol Metab, 90, 3498, 10.1210/jc.2004-2240 Hui, 2004, Beyond insulin resistance in NASH: TNF-alpha or adiponectin?, Hepatology, 40, 46, 10.1002/hep.20280 Hotamisligil, 2006, Inflammation and metabolic disorders, Nature, 444, 860, 10.1038/nature05485 Ridker, 2002, Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events, N Engl J Med, 347, 1557, 10.1056/NEJMoa021993 Park, 2004, Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men, J Gastroenterol Hepatol, 19, 694, 10.1111/j.1440-1746.2004.03362.x Anty, 2006, The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, Type 2 diabetes, and NASH, Am J Gastroenterol, 101, 1824, 10.1111/j.1572-0241.2006.00724.x Bekri, 2006, Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH, Gastroenterology, 131, 788, 10.1053/j.gastro.2006.07.007 Xu, 2003, Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance, J Clin Invest, 112, 1821, 10.1172/JCI200319451 Weisberg, 2003, Obesity is associated with macrophage accumulation in adipose tissue, J Clin Invest, 112, 1796, 10.1172/JCI200319246 Clement, 2004, Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects, Faseb J, 18, 1657, 10.1096/fj.04-2204com Wu, 2007, T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity, Circulation, 115, 1029, 10.1161/CIRCULATIONAHA.106.638379 Mohamed-Ali, 1997, Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo, J Clin Endocrinol Metab, 82, 4196, 10.1210/jc.82.12.4196 Ailhaud, 2006, Adipose tissue as a secretory organ: from adipogenesis to the metabolic syndrome, C R Biol, 329, 570, 10.1016/j.crvi.2005.12.012 Canbay, 2003, Apoptotic body engulfment by a human stellate cell line is profibrogenic, Lab Invest, 83, 655, 10.1097/01.LAB.0000069036.63405.5C Fadok, 1998, Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF, J Clin Invest, 101, 890, 10.1172/JCI1112 Richardson, 2007, Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction, Gastroenterology, 133, 80, 10.1053/j.gastro.2007.05.012 Musso, 2005, Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis, Am J Gastroenterol, 100, 2438, 10.1111/j.1572-0241.2005.00297.x Tietge, 2004, Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics, Am J Physiol Endocrinol Metab, 287, E82, 10.1152/ajpendo.00494.2003 Sohara, 2005, Elevated plasma adiponectin concentrations in patients with liver cirrhosis correlate with plasma insulin levels, Liver Int, 25, 28, 10.1111/j.1478-3231.2004.0986.x Shimada, 2007, Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis, Am J Gastroenterol, 102, 1931, 10.1111/j.1572-0241.2007.01322.x Bataller, 2003, NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis, J Clin Invest, 112, 1383, 10.1172/JCI18212 Paradis, 2001, High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis, Hepatology, 34, 738, 10.1053/jhep.2001.28055 Eriksson, 1986, Nonalcoholic steatohepatitis in obesity: a reversible condition, Acta Med Scand, 220, 83, 10.1111/j.0954-6820.1986.tb02733.x Wanless, 1990, Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors, Hepatology, 12, 1106, 10.1002/hep.1840120505 Powell, 1990, The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years, Hepatology, 11, 74, 10.1002/hep.1840110114 Lee, 1989, Nonalcoholic steatohepatitis: a study of 49 patients, Hum Pathol, 20, 594, 10.1016/0046-8177(89)90249-9 Bacon, 1994, Nonalcoholic steatohepatitis: an expanded clinical entity, Gastroenterology, 107, 1103, 10.1016/0016-5085(94)90235-6 Itoh, 1987, Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis, Am J Gastroenterol, 82, 650 Diehl, 1988, Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury, Gastroenterology, 95, 1056, 10.1016/0016-5085(88)90183-7 Donati, 2004, Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance, Gut, 53, 1020, 10.1136/gut.2003.027086 Marchesini, 2001, Nonalcoholic fatty liver disease: a feature of the metabolic syndrome, Diabetes, 50, 1844, 10.2337/diabetes.50.8.1844 Angelico, 2005, Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease, J Clin Endocrinol Metab, 90, 1578, 10.1210/jc.2004-1024 Hamaguchi, 2005, The metabolic syndrome as a predictor of nonalcoholic fatty liver disease, Ann Intern Med, 143, 722, 10.7326/0003-4819-143-10-200511150-00009 Hanley, 2005, Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study, Diabetes, 54, 3140, 10.2337/diabetes.54.11.3140 Ruttmann, 2005, Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163, 944 Austrian adults, Circulation, 112, 2130, 10.1161/CIRCULATIONAHA.105.552547 Lee, 2007, Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study, Arterioscler Thromb Vasc Biol, 27, 127, 10.1161/01.ATV.0000251993.20372.40 Chen, 2006, Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults, J Clin Gastroenterol, 40, 745, 10.1097/00004836-200609000-00016 Seppala-Lindroos, 2002, Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men, J Clin Endocrinol Metab, 87, 3023, 10.1210/jc.87.7.3023 Lakka, 2002, The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men, Jama, 288, 2709, 10.1001/jama.288.21.2709 Hu, 2004, Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women, Arch Intern Med, 164, 1066, 10.1001/archinte.164.10.1066 Targher, 2006, The International Diabetes Federation definition of the metabolic syndrome independently predicts future cardiovascular events in Type 2 diabetic patients, The Valpolicella Heart Diabetes Study Diabet Med, 23, 1270, 10.1111/j.1464-5491.2006.01940.x Despres, 2006, Abdominal obesity and metabolic syndrome, Nature, 444, 881, 10.1038/nature05488 Brea, 2005, Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study, Arterioscler Thromb Vasc Biol, 25, 1045, 10.1161/01.ATV.0000160613.57985.18 Targher, 2006, Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease, Diabetes Care, 29, 1325, 10.2337/dc06-0135 Targher, 2007, Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients, Diabetes Care, 2, 2 Villanova, 2005, Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease, Hepatology, 42, 473, 10.1002/hep.20781 Ekstedt, 2006, Long-term follow-up of patients with NAFLD and elevated liver enzymes, Hepatology, 44, 865, 10.1002/hep.21327 Ratziu, 2006, Assessing the outcome of nonalcoholic steatohepatitis ? It's time to get serious, Hepatology, 44, 802, 10.1002/hep.21391 Ob Epi. Enquête épidémiologique nationale sur le surpoids et l’obésité. Enquête INSERM/TNS Healthcare SOFRES/Roche 2006. Cortez-Pinto, 2006, Non-alcoholic steatohepatitis: from cell biology to clinical practice, J Hepatol, 44, 197, 10.1016/j.jhep.2005.09.002 Clark, 2003, The prevalence and etiology of elevated aminotransferase levels in the United States, Am J Gastroenterol, 98, 960, 10.1111/j.1572-0241.2003.07486.x de Ledinghen, 2006, Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study, J Hepatol, 45, 592, 10.1016/j.jhep.2006.05.008 Adams, 2005, The natural history of nonalcoholic fatty liver disease: a population-based cohort study, Gastroenterology, 129, 113, 10.1053/j.gastro.2005.04.014 Programme National Nutrition Santé 2006-2010. http://www.mangerbouger.fr/pnns/index.php. Harrison, 2004, A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients, Aliment Pharmacol Ther, 20, 623, 10.1111/j.1365-2036.2004.02153.x Hussein, 2007, Orlistat Reverse Fatty Infiltration and Improves Hepatic Fibrosis in Obese Patients with Nonalcoholic Steatohepatitis (NASH), Dig Dis Sci, 3, 3 Uygun, 2004, Metformin in the treatment of patients with non-alcoholic steatohepatitis, Aliment Pharmacol Ther, 19, 537, 10.1111/j.1365-2036.2004.01888.x Nair, 2004, Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial, Aliment Pharmacol Ther, 20, 23, 10.1111/j.1365-2036.2004.02025.x Bugianesi, 2005, A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease, Am J Gastroenterol, 100, 1082, 10.1111/j.1572-0241.2005.41583.x Basaranoglu, 1999, A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis, J Hepatol, 31, 384, 10.1016/S0168-8278(99)80243-8 Neuschwander-Tetri, 2003, Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone, Hepatology, 38, 1008, 10.1053/jhep.2003.50420 Promrat, 2004, A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis, Hepatology, 39, 188, 10.1002/hep.20012 Belfort, 2006, A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis, N Engl J Med, 355, 2297, 10.1056/NEJMoa060326 Ratziu, 2006, A one year randomized, placebo-controlled, double-blind trial of rosiglitazone in non alcoholic steatohepatitis: results of the FLIRT pilot trial, Hepatology, 44, 201A Lutchman, 2007, The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis, Hepatology, 46, 424, 10.1002/hep.21661 Isley, 2003, Hepatotoxicity of thiazolidinediones, Expert Opin Drug Saf, 2, 581, 10.1517/14740338.2.6.581 Nissen, 2007, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes, N Engl J Med, 356, 2457, 10.1056/NEJMoa072761 Home, 2007, Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis, N Engl J Med, 357, 28, 10.1056/NEJMoa073394 Nathan, 2007, Rosiglitazone and cardiotoxicity-weighing the evidence, N Engl J Med, 357, 64, 10.1056/NEJMe078117 Psaty, 2007, The record on rosiglitazone and the risk of myocardial infarction, N Engl J Med, 357, 67, 10.1056/NEJMe078116 Balas, 2007, Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis, J Hepatol, 24, 24 McCullough, 2006, Thiazolidinediones for nonalcoholic steatohepatitis-promising but not ready for prime time, N Engl J Med, 355, 2361, 10.1056/NEJMe068232 Despres, 2005, Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia, N Engl J Med, 353, 2121, 10.1056/NEJMoa044537 Van Gaal, 2005, Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study, Lancet, 365, 1389, 10.1016/S0140-6736(05)66374-X Scheen, 2006, Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study, Lancet, 368, 1660, 10.1016/S0140-6736(06)69571-8 Teixeira-Clerc, 2006, CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis, Nat Med, 12, 671, 10.1038/nm1421 Ding, 2006, Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice, Hepatology, 43, 173, 10.1002/hep.21006 Tushuizen, 2006, Incretin mimetics as a novel therapeutic option for hepatic steatosis, Liver Int, 26, 1015, 10.1111/j.1478-3231.2006.01315.x Sjostrom, 2004, Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery, N Engl J Med, 351, 2683, 10.1056/NEJMoa035622 Dixon, 2004, Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss, Hepatology, 39, 1647, 10.1002/hep.20251 Buchwald, 2004, Bariatric surgery: a systematic review and meta-analysis, Jama, 292, 1724, 10.1001/jama.292.14.1724 Klein, 2006, Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease, Gastroenterology, 130, 1564, 10.1053/j.gastro.2006.01.042 Mathurin, 2006, The evolution of severe steatosis after bariatric surgery is related to insulin resistance, Gastroenterology, 130, 1617, 10.1053/j.gastro.2006.02.024 Sjöström, 2007, Effects of Bariatric surgery on mortality in swedish obese subjects, N Eng J Med, 357, 741, 10.1056/NEJMoa066254 Adams, 2007, N Eng J Med, 357, 753, 10.1056/NEJMoa066603 Ratziu, 2007, Peut-on traiter la stéatohépatite métabolique ?, Gastroenterol Clin Biol, 31, 333, 10.1016/S0399-8320(07)89386-9